Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update 6h
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer 02 February
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026 27 January
